From: Intra-mammary lymph nodes, an overlooked breast cancer prognostic tool?
Variables | Benign IMLNs Received Neoadj CTH (N = 13) | Malignant IMLNs Received Neoadj CTH (N = 13) | P-value |
---|---|---|---|
Neoadjuvant chemotherapy | |||
Yes | 13 (31%) | 13 (27.1%) | 0.686C |
No | 29 (69%) | 35 (72.9%) | |
AxLN response after neoadjuvant chemotherapy | |||
N-A | 6 (46.2%) | 4 (30.8%) | 0.199C |
N-B | 1 (7.7%) | 0 (0.0%) | |
N-C | 3 (23.1%) | 1 (7.7%) | |
N-D | 3 (23.1%) | 8 (61.5%) | |
IMLN response after neoadjuvant chemotherapy | |||
N-A | 12 (92.3%) | 0 (0%) | < 0.001C |
N-B | 1 (7.7%) | 0 (0%) | |
N-D | 0.(0%) | 13 (100%) | |
Miller grade tumor | |||
1 | 0 (0%) | 3 (23.1%) | |
2 | 3 (23.1%) | 7 (53.8%) | |
3 | 1 (7.7%) | 0 (0%) | |
4 | 1 (7.7%) | 1 (7.7%) | 0.020C |
5 | 8 (61.5%) | 2 (15.4%) |